OBJECTIVES: To determine whether preoperative laboratory values are independently associated with death from clinically confined clear cell renal cell carcinoma (RCC) after radical nephrectomy. METHODS: We identified 1707 patients with clinically confined (pNx/pN0, pM0), unilateral, sporadic clear cell RCC treated with radical nephrectomy between 1970 and 2002. Associations of abnormal preoperative laboratory values including hypercalcemia, anemia, elevated erythrocyte sedimentation rate (ESR), and elevated alkaline phosphatase with death from RCC were evaluated using Cox proportional hazards regression models, both univariately and multivariately by adjusting for known prognostic features of the 2002 primary tumor classification, tumor size, nuclear grade, and coagulative tumor necrosis. RESULTS: At last follow-up, 1009 patients had died, including 425 who died from RCC at a median of 3.0 years after surgery (range, 0 to 26 years). Even after adjusting for known prognostic features, 9% of patients with preoperative hypercalcemia exhibited significantly increased likelihood of dying from RCC compared with patients with normal or lower levels of serum calcium (relative ration [RR] 1.64; P = 0.002). Similarly, preoperative anemia (35% of patients; RR 1.27; P = 0.026) and elevated ESR (44% of patients; RR 1.66; P = 0.003) portended an increased risk of death from RCC even after multivariate adjustment. CONCLUSIONS: Abnormal preoperative laboratory values including hypercalcemia, anemia, and elevated ESR are independently associated with increased risk of cancer-specific death from clinically confined clear cell RCC. Consideration of these variables in future models may improve prognostic accuracy. We believe these factors should be routinely assessed and included in prospective studies of outcome in RCC patients.
OBJECTIVES: To determine whether preoperative laboratory values are independently associated with death from clinically confined clear cell renal cell carcinoma (RCC) after radical nephrectomy. METHODS: We identified 1707 patients with clinically confined (pNx/pN0, pM0), unilateral, sporadic clear cell RCC treated with radical nephrectomy between 1970 and 2002. Associations of abnormal preoperative laboratory values including hypercalcemia, anemia, elevated erythrocyte sedimentation rate (ESR), and elevated alkaline phosphatase with death from RCC were evaluated using Cox proportional hazards regression models, both univariately and multivariately by adjusting for known prognostic features of the 2002 primary tumor classification, tumor size, nuclear grade, and coagulative tumor necrosis. RESULTS: At last follow-up, 1009 patients had died, including 425 who died from RCC at a median of 3.0 years after surgery (range, 0 to 26 years). Even after adjusting for known prognostic features, 9% of patients with preoperative hypercalcemia exhibited significantly increased likelihood of dying from RCC compared with patients with normal or lower levels of serum calcium (relative ration [RR] 1.64; P = 0.002). Similarly, preoperative anemia (35% of patients; RR 1.27; P = 0.026) and elevated ESR (44% of patients; RR 1.66; P = 0.003) portended an increased risk of death from RCC even after multivariate adjustment. CONCLUSIONS: Abnormal preoperative laboratory values including hypercalcemia, anemia, and elevated ESR are independently associated with increased risk of cancer-specific death from clinically confined clear cell RCC. Consideration of these variables in future models may improve prognostic accuracy. We believe these factors should be routinely assessed and included in prospective studies of outcome in RCCpatients.
Authors: Shomik Sengupta; Christine M Lohse; John C Cheville; Bradley C Leibovich; R Houston Thompson; W Scott Webster; Igor Frank; Horst Zincke; Michael L Blute; Eugene D Kwon Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke Journal: J Urol Date: 2002-12 Impact factor: 7.450
Authors: Kyle A Furge; Kerry A Lucas; Masayuki Takahashi; Jun Sugimura; Eric J Kort; Hiro-omi Kanayama; Susumu Kagawa; Philip Hoekstra; John Curry; Ximing J Yang; Bin T Teh Journal: Cancer Res Date: 2004-06-15 Impact factor: 12.701
Authors: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Bradley C Leibovich; Horst Zincke Journal: J Urol Date: 2003-12 Impact factor: 7.450
Authors: Hyung L Kim; Arie S Belldegrun; Danielo G Freitas; Matthew H T Bui; Ken-ryu Han; Frederick J Dorey; Robert A Figlin Journal: J Urol Date: 2003-11 Impact factor: 7.450
Authors: Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Igor Frank; Eugene D Kwon; Amy L Weaver; Alexander S Parker; Horst Zincke Journal: Cancer Date: 2003-04-01 Impact factor: 6.860
Authors: Daniel M Moreira; Boris Gershman; Christine M Lohse; Stephen A Boorjian; John C Cheville; Bradley C Leibovich; Robert Houston Thompson Journal: World J Urol Date: 2016-02-25 Impact factor: 4.226
Authors: Reza Mehrazin; Robert G Uzzo; Alexander Kutikov; Karen Ruth; Jeffrey J Tomaszewski; Essel Dulaimi; Serge Ginzburg; Philip H Abbosh; Timothy Ito; Anthony T Corcoran; David Y T Chen; Marc C Smaldone; Tahseen Al-Saleem Journal: Urol Oncol Date: 2014-07-11 Impact factor: 3.498
Authors: Emily B Southard; Alanna Roff; Tracey Fortugno; John P Richie; Matthew Kaag; Vernon M Chinchilli; Jarmo Virtamo; Demetrius Albanes; Stephanie Weinstein; Robin Taylor Wilson Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-15 Impact factor: 4.254
Authors: Ryan Sun; Rodney H Breau; Ranjeeta Mallick; Simon Tanguay; Frederic Pouliot; Anil Kapoor; Luke T Lavallée; Antonio Finelli; Alan I So; Ricardo A Rendon; Adrian S Fairey; Jean-Baptiste Lattouf; Jun Kawakami; Bimal Bhindi; Naveen S Basappa; Lori A Wood; Georg A Bjarnason; Daniel Y C Heng; Rahul K Bansal Journal: Can Urol Assoc J Date: 2021-04 Impact factor: 1.862
Authors: Brian W Cross; Timothy V Johnson; Austin B Derosa; Kenneth Ogan; John G Pattaras; Peter T Nieh; Omer Kucuk; Wayne B Harris; Viraj A Master Journal: Int J Surg Oncol Date: 2012-07-29